{
  "label": "q_cs03_q10_evidence",
  "artifact_type": "question",
  "artifact_id": "sha256:48e7762375f0aa8a2cfa1e6dd449561bf57de2356221e0008a143075e322fa73",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:f7717f742ab207de4172b6a6cccbd34d4b92f4ef7d31135025c1a0eafc15e02c"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:01:44.859899",
  "content": "{\n  \"question_id\": \"cs03_q10_evidence\",\n  \"scope_id\": \"clinical_signal_03\",\n  \"checkpoint_after\": 5,\n  \"question_type\": \"evidence_sufficiency\",\n  \"prompt\": \"Is there sufficient data at this point to evaluate the safety profile of LNS-4821?\",\n  \"ground_truth\": {\n    \"canonical_answer\": \"No. Only 5 weeks of data from the enrollment ramp phase are available. The subject population is too small and exposure duration too short to draw conclusions about the drug's safety profile.\",\n    \"required_evidence_refs\": [\n      \"clinical_signal_03_ep_003\"\n    ],\n    \"key_facts\": []\n  }\n}",
  "metadata": {
    "question_id": "cs03_q10_evidence",
    "question_type": "evidence_sufficiency",
    "checkpoint_after": 5,
    "scope_id": "clinical_signal_03",
    "layer_name": "questions",
    "layer_level": 3,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "6e7c8d0317261f4c8d0cd7d54ad8afe93ba5bf0a1d7bf910ce7a0d17de3cd1a5",
      "components": {
        "transform": "a7d463dc476b419c96a5f454f481b455ca81a8d8ee3904631b7729963317406f",
        "inputs": "2ef0a6576c887dd8"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a7d463dc476b419c96a5f454f481b455ca81a8d8ee3904631b7729963317406f",
      "components": {
        "transform_id": "3176c030aaa3a69e",
        "source": "929fe273ac2dab06",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}